These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 35127255)
1. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. Wachsmann TLA; Wouters AK; Remst DFG; Hagedoorn RS; Meeuwsen MH; van Diest E; Leusen J; Kuball J; Falkenburg JHF; Heemskerk MHM Oncoimmunology; 2022; 11(1):2033528. PubMed ID: 35127255 [TBL] [Abstract][Full Text] [Related]
2. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942 [TBL] [Abstract][Full Text] [Related]
3. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Zurko JC; Xu H; Chaney K; Schneider D; Szabo A; Hari P; Johnson BD; Shah NN Cytotherapy; 2022 Aug; 24(8):767-773. PubMed ID: 35597752 [TBL] [Abstract][Full Text] [Related]
4. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR". Teppert K; Wang X; Anders K; Evaristo C; Lock D; Künkele A Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498890 [TBL] [Abstract][Full Text] [Related]
5. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878 [TBL] [Abstract][Full Text] [Related]
6. Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T Front Immunol; 2022; 13():770132. PubMed ID: 35154098 [TBL] [Abstract][Full Text] [Related]
7. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Jensen MC; Riddell SR Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794 [TBL] [Abstract][Full Text] [Related]
8. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells. MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835 [TBL] [Abstract][Full Text] [Related]
9. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Martinez M; Moon EK Front Immunol; 2019; 10():128. PubMed ID: 30804938 [TBL] [Abstract][Full Text] [Related]
10. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. Anikeeva N; Panteleev S; Mazzanti NW; Terai M; Sato T; Sykulev Y J Biol Chem; 2021 Sep; 297(3):101033. PubMed ID: 34371020 [TBL] [Abstract][Full Text] [Related]
11. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Shafer P; Kelly LM; Hoyos V Front Immunol; 2022; 13():835762. PubMed ID: 35309357 [TBL] [Abstract][Full Text] [Related]
12. Who wins the combat, CAR or TCR? Yun K; Siegler EL; Kenderian SS Leukemia; 2023 Oct; 37(10):1953-1962. PubMed ID: 37626090 [TBL] [Abstract][Full Text] [Related]
13. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Hiltensperger M; Krackhardt AM Front Immunol; 2023; 14():1121030. PubMed ID: 36949949 [TBL] [Abstract][Full Text] [Related]
14. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181 [TBL] [Abstract][Full Text] [Related]
15. Exhaustion of CAR T cells: potential causes and solutions. Kouro T; Himuro H; Sasada T J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821 [TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
17. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647 [TBL] [Abstract][Full Text] [Related]
18. Generation of CAR-T cells using lentiviral vectors. Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998 [TBL] [Abstract][Full Text] [Related]